These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25083132)

  • 21. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linagliptin: from bench to bedside.
    Doupis J
    Drug Des Devel Ther; 2014; 8():431-46. PubMed ID: 24851042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Expert Opin Investig Drugs; 2010 Jan; 19(1):133-40. PubMed ID: 19947894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ; Setter SM
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Ramirez G; Morrison AD; Bittle PA
    Endocr Pract; 2013; 19(6):1025-34. PubMed ID: 23757605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linagliptin as add-on therapy for type 2 diabetes - an overview.
    Brown DX; Choudhury M; Evans M
    Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacological and clinical profiles of the DPP-4 inhibitor linagliptin (Trazenta)].
    Ohmura T; Hayashi N; Encinas J
    Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):174-83. PubMed ID: 22498683
    [No Abstract]   [Full Text] [Related]  

  • 30. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
    Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
    Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
    Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
    Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linagliptin: in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2011 Mar; 71(5):611-24. PubMed ID: 21443284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
    Groop PH; Del Prato S; Taskinen MR; Owens DR; Gong Y; Crowe S; Patel S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2014 Jun; 16(6):560-8. PubMed ID: 24612167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.
    Lajara R
    Expert Opin Pharmacother; 2012 Dec; 13(18):2663-71. PubMed ID: 23137412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frailty and diabetes.
    Sinclair A; Morley J
    Lancet; 2013 Oct; 382(9902):1386-7. PubMed ID: 23948126
    [No Abstract]   [Full Text] [Related]  

  • 39. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
    Kawamori R; Inagaki N; Araki E; Watada H; Hayashi N; Horie Y; Sarashina A; Gong Y; von Eynatten M; Woerle HJ; Dugi KA
    Diabetes Obes Metab; 2012 Apr; 14(4):348-57. PubMed ID: 22145698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.